News and Press Releases
May 19, 2009:
Agennix Receives Fast Track Designation From FDA For Talactoferrin In Combination With Sunitinib For Renal Cell Carcinoma
Feb. 17, 2009:
GPC Biotech and Agennix Announce Proposed Merger
July 1, 2008:
Results Published In The Journal Cancer Demonstrate That Oral Talactoferrin Alfa Is Active As Monotherapy In Previously Treated Patients With Metastatic Renal Cell Carcinoma
April 22, 2008:
Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study Of Oral Talactoferrin In Severe Sepsis
February 26, 2008:
Oral Talactoferrin Alfa Improves Overall Survival in Patients with Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting
January 17, 2008:
Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer
June 4, 2007:
Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients with Refractory Non-Small Cell Lung Cancer Treated with Agennix's Oral Talactoferrin
October 12, 2006:
Agennix Receives FDA Orphan Drug Designation For Talactoferrin Alfa In Renal Cell Carcinoma
October 5, 2006:
Agennix Receives FDA Fast Track Designation for Talactoferrin Alfa in Non-Small Cell Lung Cancer and Diabetic Foot Ulcers
June 13, 2005:
Agennix's Topical Talactoferrin Improved Healing Of Diabetic Ulcers
May 17, 2005:
Agennix's Oral Talactoferrin Improved Response Rates, Time to Progression and Duration of Response when Combined with First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
April 19, 2005:
Agennix’s Oral Talactoferrin Substantially Improved Response Rates when Combined with First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
March 30, 2005:
Agennix Raises $22 Million in Private Financing
August 18, 2004:
Agennix Data Published in the International Journal of Cancer; Journal Features Cover Image of Tumor Regression Following rhLF-Treatment
June 9, 2004:
VAMC and Agennix Release Lactoferrin Cancer Trial Results at ASCO
March 30, 2004:
Agennix Presents Positive RhLF Cancer Results at AACR Meeting
March 9, 2004:
Agennix Composition of Matter Patent on Recombinant Human Lactoferrin Upheld in Europe
Sept. 17, 2003:
Agennix Inc. Receives $850,000 NIH Funding to Support Clinical Trials of rhLF Gel for Treatment of Patients with Diabetic Foot Ulcers
June 30, 2003:
Agennix appoints Dr. Frank Young Chairman of its Board of Directors
June 18, 2003:
Agennix Inc. Presents Positive Results Showing Accelerated Wound Healing and Wound Closure with Topical Recombinant Human Lactoferrin
May 22, 2003:
VAMC and Agennix Successfully Complete Safety Phase of Lactoferrin Cancer Trial
Sept. 17, 2002:
Agennix and DSM Pharmaceutical Products announce opening of recombinant human lactoferrin manufacturing facility
May 29, 2002:
Agennix Completes $20 Million Private Placement Financing
May 14, 2001:
Dr. Waun Ki Hong Joins Agennix's Scientific Advisory Board
May 10, 2001:
Agennix Receives Broad Patent
About Agennix
|
Talactoferrin
|
News & Media
|
Careers
Site Map
|
Terms of Use
© 2002 Agennix, Inc. All rights reserved.
